Calithera Biosciences, Inc. (CALA) financial statements (2021 and earlier)

Company profile

Business Address 343 OYSTER POINT BLVD #200
SOUTH SAN FRANCISCO, CA 94080
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:10760511645272102
Cash and cash equivalents107605148116102
Short-term investments   1154164 
Other undisclosed cash, cash equivalents, and short-term investments    02 
Receivables2021   
Other undisclosed current assets1099873212
Total current assets:1191601401685472104
Noncurrent Assets
Operating lease, right-of-use asset6 
Property, plant and equipment1112111
Long-term investments and receivables   22 2 
Long-term investments   22 2 
Restricted cash and investments0000000
Other noncurrent assets 01000 
Other undisclosed noncurrent assets 7     
Total noncurrent assets:79225131
TOTAL ASSETS:1261691431925576105
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities9201510446
Accounts payable2211011
Accrued liabilities118149433
Employee-related liabilities5     1
Deferred revenue and credits29   
Other undisclosed current liabilities10     (1)
Total current liabilities:18201539444
Noncurrent Liabilities
Long-term debt and lease obligation5      
Operating lease, liability5 
Liabilities, other than long-term debt  13000
Deferred revenue and credits3000
Deferred rent credit  1
Other liabilities      0
Other undisclosed noncurrent liabilities(5)7     
Total noncurrent liabilities:5713000
Total liabilities:23261642544
Stockholders' equity
Stockholders' equity attributable to parent1021421271505072100
Common stock0000000
Additional paid in capital479428323301172156152
Accumulated other comprehensive income (loss)00(0)(0)(0)(0) 
Accumulated deficit(376)(286)(196)(150)(123)(84)(52)
Total stockholders' equity:1021421271505072100
TOTAL LIABILITIES AND EQUITY:1261691431925576105

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenue, net26   
Sublease income0 
Gross profit:0 2226   
Operating expenses(91)(93)(80)(56)(38)(33)(22)
Other undisclosed operating loss(0)      
Operating loss:(91)(93)(57)(30)(38)(33)(22)
Nonoperating income (expense)
(Investment Income, Nonoperating)
010(0)   
Other undisclosed income from continuing operations before equity method investments, income taxes1222   
Net loss:(90)(90)(55)(28)(38)(33)(22)
Other undisclosed net income attributable to parent    000
Net loss available to common stockholders, diluted:(90)(90)(55)(28)(38)(33)(22)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(90)(90)(55)(28)(38)(33)(22)
Comprehensive loss:(90)(90)(55)(28)(38)(33)(22)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)00(0)00 
Comprehensive loss, net of tax, attributable to parent:(90)(90)(54)(28)(38)(33)(22)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: